Mutations in the DNA-Binding Domain of NR2E3 Affect In Vivo Dimerization and Interaction with CRX by Roduit, Raphael et al.
Mutations in the DNA-Binding Domain of NR2E3 Affect In
Vivo Dimerization and Interaction with CRX
Raphael Roduit
1,2.*, Pascal Escher
1,2., Daniel F. Schorderet
1,2,3
1IRO, Institute for Research in Ophthalmology, Sion, Switzerland, 2Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland, 3EPFL, Ecole
Polytechnique Fe ´de ´rale de Lausanne, Lausanne, Switzerland
Abstract
Background: NR2E3 (PNR) is an orphan nuclear receptor essential for proper photoreceptor determination and
differentiation. In humans, mutations in NR2E3 have been associated with the recessively inherited enhanced short
wavelength sensitive (S-) cone syndrome (ESCS) and, more recently, with autosomal dominant retinitis pigmentosa (adRP).
NR2E3 acts as a suppressor of the cone generation program in late mitotic retinal progenitor cells. In adult rod
photoreceptors, NR2E3 represses cone-specific gene expression and acts in concert with the transcription factors CRX and
NRL to activate rod-specific genes. NR2E3 and CRX have been shown to physically interact in vitro through their respective
DNA-binding domains (DBD). The DBD also contributes to homo- and heterodimerization of nuclear receptors.
Methodology/Principal Findings: We analyzed NR2E3 homodimerization and NR2E3/CRX complex formation in an in vivo
situation by Bioluminescence Resonance Energy Transfer (BRET
2). NR2E3 wild-type protein formed homodimers in
transiently transfected HEK293T cells. NR2E3 homodimerization was impaired in presence of disease-causing mutations in
the DBD, except for the p.R76Q and p.R104W mutant proteins. Strikingly, the adRP-linked p.G56R mutant protein interacted
with CRX with a similar efficiency to that of NR2E3 wild-type and p.R311Q proteins. In contrast, all other NR2E3 DBD-mutant
proteins did not interact with CRX. The p.G56R mutant protein was also more effective in abolishing the potentiation of
rhodospin gene transactivation by the NR2E3 wild-type protein. In addition, the p.G56R mutant enhanced the
transrepression of the M- and S-opsin promoter, while all other NR2E3 DBD-mutants did not.
Conclusions/Significance: These results suggest different disease mechanisms in adRP- and ESCS-patients carrying NR2E3
mutations. Titration of CRX by the p.G56R mutant protein acting as a repressor in trans may account for the severe clinical
phenotype in adRP patients.
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Introduction
NR2E3 (MIM#604485) is a photoreceptor-specific nuclear
receptor (PNR) that belongs to the nuclear hormone receptor
superfamily of ligand-modulated transcription factors [1]. The
physiological function of NR2E3 is to regulate the proper
differentiation and maturation of rod and cone photoreceptors,
in an intricate regulatory network including the cone-rod
homeobox (CRX) (MIM#602225) and the neural retina leucine
zipper (NRL) (MIM#162080) transcription factors [2]. In late
mitotic retinal progenitor cells, NR2E3 is thought to suppress the
cone generation program [3], while in adult differentiated rods,
NR2E3 exerts a dual function by repressing cone-specific genes
[4,5] and by activating several rod-specific genes, including
rhodopsin [4,6,7].
All nuclear receptors (NRs) share a common structural
organization composed of four main domains [8]. First, the highly
variable N-terminal A/B domain comprises a ligand-independent
activation function (AF-1). Second, the most conserved C domain
forms a 70-amino acid long DNA-binding domain (DBD)
consisting of two Cys4 zinc fingers. The C-terminus of the first
Cys4 zinc finger comprises the so-called P-box that specifically
contacts nucleotides located in the DNA major groove. Three
discriminatory amino acids (underlined below) determine DNA
binding, EGCKS and EGCKG in NR2 family members and
orphan NRs [1]. NR2E subfamily members exhibit exceptional P-
boxes with NGCSG sequence in NR2E3 and DGCSG in NR2E1
and NR2E2. The consensus core motif recognized by NR2E
proteins appears to be AAGTCA [1,9]. The region between the
first two Cys residues of the second Cys4 zinc finger forms the so-
called D-box, which is involved in DBD dimerization and
recognition of the spacing between two adjacent core motifs.
Third, the flexible D domain, or so-called hinge domain, links the
DBD to the ligand-binding domain (LBD) and contains the
nuclear localization signal which may overlap on the DBD.
Fourth, the C-terminal E/F domain, or LBD, consists of a
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a strong dimerization function and the ligand-dependent AF-2
transactivation function.
The first NRs most likely acted as monomers in a ligand-
independent fashion [10]. NRs then acquired the ability to homo-
or heterodimerize and to interact with specific ligands, allowing
the regulation of more diverse and more complex physiological
processes. Within the NR2E subfamily, Drosophila tailless
(NR2E2) and its chick and mouse orthologs Tlx (NR2E1) bind
their target genes as monomers [11,12]. Homodimers have also
been reported to bind DNA, but to a lesser extent. Interestingly,
NR2E3 also acts as a transcriptional repressor (see above), but, in
contrast to NR2E1, in vitro DNA binding experiments suggested
binding to a direct repeat of the core motif spaced by one
nucleotide (so-called DR1 response element), the consensus
binding site being 59-(A/G)AG(A/G)TCAAA(A/G)(A/G)TCA-39
[1,5]. It is therefore tempting to speculate that in addition to
unique P-box and D-box sequences and to a spatial expression
uniquely restricted to photoreceptors, NR2E3 dimer formation
can increase target specificity when compared to NR2E1, another
NR expressed in the retina [12].
In humans, mutations in NR2E3 have first been associated with
the recessively inherited enhanced short wavelength sensitive (S-)
cone syndrome (ESCS) (MIM #268100) [13]. ESCS is charac-
terized by unique full-field and spectral electroretinographic
findings with hyperfunction of S-cones (‘blue’ cones) and impaired
M-cones, L-cones and rods function [14]. To date, 32 different
mutations located in the evolutionary-conserved DBD and LBD of
NR2E3 have been linked to ESCS with c.932G.A (p.R311Q)
being the most prevalent [13,15–19]. A c.166G.A (p.G56R)
mutation located in the first Cys4 zinc finger of NR2E3 gene was
shown to cause autosomal dominant (ad) retinitis pigmentosa (RP)
(adRP), termed RP37 (MIM #611131) [20–22]. The phenotype
corresponded to that seen in classic adRP, with progressive
degeneration of rods and subsequent involvement of cones.
In this study, we analysed by Bioluminescence Resonance
Energy Transfer 2 (BRET
2) [23–27], NR2E3 homodimerization
and interaction with CRX for all reported NR2E3 mutations
located in the DBD. Transcriptional activity of the different
mutants was also tested on rhodopsin, S- and M-opsin promoter
reporter constructs. These analyses showed a distinct in vivo
protein-protein interaction of the adRP-linked p.G56R mutant
protein with CRX, comparable to that of wild-type NR2E3, but
contrasting with the other ESCS-linked DBD mutants. This
provided a novel molecular basis for the clinical differences seen in
human patients affected by adRP versus those affected by ESCS
[19].
Results
NR2E3 homodimerization in HEK293T cells
To analyze a potential dimerization of NR2E3, we expressed
the human NR2E3 wild-type protein by transient transfection in
heterologous HEK293T cells. Total protein extracts were
separated by SDS-PAGE under denaturing and non-denaturing
conditions (figure 1A). Western blot analysis with an anti-NR2E3
antibody detected a band of the expected size at 45 kDa under
denaturing conditions, while a fainter additional reactive band was
observed at 90 kDa under native conditions. This result suggested
that NR2E3 was able to form homodimers in vivo.
To analyze the dimerization of NR2E3 in vivo, we resorted to the
BRET
2 technique. We transiently transfected HEK293T cells with
vectors expressing the Renilla Luciferase (RLuc) fused to the C-
terminus of NR2E3 (NR2E3-RLuc) and the Green Fluorescent
Protein (GFP
2) fused to the N-terminus of NR2E3 (GFP
2-NR2E3).
As negative controls, cells were transfected with vectors expressing
1) RLuc alone, 2) GFP
2 and NR2E3-RLuc and 3) RLuc and
GFP
2-NR2E3. Figure 1B showed the both negative controls 1 and
2, and positive experiment. Moreover, this fluorescence imaging
showed that the GFP
2-NR2E3 fusion protein was correctly
localized to the nucleus, whereas the GFP
2 protein showed both
cytosolic and nuclear expression. By BRET
2 analysis, we were able
to measure comparable GFP
2 fluorescence levels in cells
expressing either the GFP
2 or the GFP
2–NR2E3 proteins, whereas
low fluorescence levels were observed in controls transfected only
with the RLuc expression vector (figure 1C, upper panel). In
addition, when the Renilla Luciferase substrate, coelanterazine h,
was added to the cells, we observed similar levels of luminescence
in all experimental conditions (figure 1C, middle panel). These
data confirmed that similar levels of protein expression occurred in
both control and experimental conditions. Finally, we measured
the BRET
2 ratio (see Material & Methods) and observed a
significant increase only in the presence of both GFP
2-NR2E3 and
NR2E3-RLuc (figure 1C, lower panel). In controls, where either
GFP
2-NR2E3 was expressed with RLuc, or NR2E3-RLuc with
GFP
2, the BRET
2 ratios were very low.
We then tested whether NR2E3 dimer formation was
dependent upon the localization of the donor (GFP
2) or the
acceptor (RLuc) protein in the NR2E3 fusion protein. We
transfected HEK293T cells with vectors expressing NR2E3 fused
to the N-terminus or the C-terminus of either GFP
2 or RLuc.
Again, a significant increase in BRET
2 ratios was observed in
presence of all combinations of NR2E3 fusion proteins, while
protein expression levels (NR2E3-GFP
2 or GFP
2-NR2E3 fluores-
cence) were comparable in each condition. These results suggested
that the orientation of the fusions was not interfering with
dimerization (figure 2A).
To exclude the possibility that the increase in BRET
2 ratios was
due to non-specific interactions of overexpressed proteins, we
performed a dose-dependency experiment (figures 2B, 2C and
S1A). A constant amount of RLuc or RLuc-NR2E3 was expressed
in the presence of increasing amounts of GFP
2-NR2E3. In these
conditions, we observed a dose-dependent increase of the BRET
2
ratios, with a significant increase even at the lowest GFP
2-NR2E3
expression levels (0.5 mg of expression vector). This further
confirmed the specificity of the NR2E3 homodimerization.
NR2E3/CRX interactions in HEK293T cells
As a physical interaction between NR2E3 and CRX through
their respective DBDs was previous reported in vitro [4], we
decided to analyze this interaction by BRET
2 techniques. We
transiently transfected HEK293T cells with vectors expressing
GFP
2 or NR2E3-GFP
2, in presence of either RLuc or a fusion
protein where the human CRX protein was fused in N-terminus of
RLuc (Crx-RLuc). We were able to measure similar GFP
2
fluorescence levels in cells expressing either GFP
2 or NR2E3-
GFP
2, while low fluorescence levels were observed in control
conditions with RLuc (figure 3A, upper panel). We observed a
slight decrease in Renilla luminescence levels in presence of Crx-
RLuc, as compared to RLuc (figure 3A, middle panel).
Importantly, we observed a significant increase of the BRET
2
ratio only in presence of both NR2E3-GFP
2 and Crx-RLuc
(figure 3A, lower panel). BRET
2 ratios were lower in both control
conditions (RLuc/NR2E3-GFP
2 or Crx-RLuc/GFP
2).
We then tested whether the localization of CRX in the fusion
protein was important for NR2E3/CRX protein interactions
(figure 3B). The highest BRET
2 ratios, i.e. the most efficient
NR2E3/CRX protein interactions, were obtained when CRX was
NR2E3 In Vivo Interactions
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ratio was significantly decreased when CRX was fused to the N-
terminus of RLuc (Crx-RLuc). Similar protein expression levels
(NR2E3-GFP
2 or GFP
2-NR2E3 fluorescence) were observed in all
performed conditions. These results showed that the orientation of
the fusion proteins was important and suggested that the N-
terminal part of CRX, where the DBD is located, had to be
accessible for efficient NR2E3/CRX interactions.
We also performed a dose-dependency experiment, in presence
of a constant amount of either RLuc or Crx-RLuc on the one
hand, and, increasing amounts of NR2E3-GFP
2 on the other hand
(figures 3C and S1B). In this experiment, we observed a significant
increase of the BRET
2 ratio even at low amounts of NR2E3-GFP
2
(0.5 mg). Taken together, these results confirmed a specific in vivo
interaction between NR2E3 and CRX.
BRET
2 analysis of DBD mutations on NR2E3 dimerization
and CRX interaction
To elucidate the molecular mechanisms by which mutations
located in a same functional domain of NR2E3, i.e. the DBD,
cause different clinical phenotypes, we chose to generate eight
NR2E3 mutant proteins and tested their effect on dimerization.
Seven of these mutations were localized in the DBD, i.e. the adRP-
linked p.G56R mutation and the ESCS-linked p.R76Q, p.R76W,
p.G88W, p.R97H, p.R104Q and p.R104W mutations. Addition-
ally, we tested the common causal mutation for ESCS located in
the LBD, p.R311Q. All mutations were introduced in the
pcDNA3.1/HisC-hNR2E3 mammalian expression vector by
site-directed mutagenesis (Table S1) and then subcloned into
GFP
2 vectors. The different NR2E3 mutant proteins (GFP
2-
NR2E3MUT) showed proper nuclear localization and protein
Figure 1. NR2E3 homodimerization analyzed by Western blot and Bioluminescence Resonance Energy Transfer (BRET
2). A) HEK293T
cells were transiently transfected in 60-mm plates with either 3 mg of an empty pcDNA3 vector or a pcDNA-NR2E3-His/C vector. Forty-eight hours
after transfection, cell lysates were separated on a 8% PAA-gel in both non-denaturing (left panel) and denaturing (right panel) conditions. NR2E3 was
immunodetected by Western blot with an anti-NR2E3 antibody. Molecular weights are indicated on the left side in kDa. B–C) For BRET
2 analysis,
HEK293T cells were transiently transfected with 3 mg of RLuc, RLuc/GFP
2-NR2E3, GFP
2-NR2E3/NR2E3-RLuc and NR2E3-RLuc/GFP
2 vectors. B) GFP
fluorescence and localization analysis by fluorescence microscopy in cells transfected with RLuc, NR2E3-RLuc/GFP
2 and NR2E3-RLuc/GFP
2-NR2E3. C)
NR2E3 homodimerization analyzed by BRET
2 48 h after transfection. GFP
2 fluorescence was quantified at 515 nm after an excitation at 485 nm (upper
graph in black bars). After addition of the renilla luciferase substrate, Coelanterazine h luciferase luminescence was measured (middle graph in white
bars). Fluorescence and luminescence levels are in arbitrary units. Finally, BRET
2 ratio was measured in the four different conditions (lower graph in
grey bars). BRET
2 sesults were expressed as mean6SEM of 3 experiments, p,0.003 (NR2E3-RLuc/GFP
2-NR2E3) vs. both controls (NR2E3-RLuc/GFP
2
and RLuc/GFP
2-NR2E3). Protein expression of NR2E3 fused either with GFP
2 (GFP-NR2E3: 74 kDa) or RLuc (NR2E3-RLuc: 82 kDa) was assessed by
Western blot analysis. We used a 10% PAA-gel to separate proteins and an anti-NR2E3 antibody to detect NR2E3 fusion proteins (panel, below).
doi:10.1371/journal.pone.0007379.g001
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cells (figures S2 and S3A).
To test whether these mutations altered the homodimerization
of NR2E3, we expressed wild-type NR2E3 fused to RLuc
(NR2E3WT-RLuc) in presence of equal amounts of each NR2E3
mutant fused to GFP
2 (GFP
2-NR2E3MUT) (figure 4A). For each
experiment, we performed three control transfections: 1) RLuc
alone to measure background fluorescence levels, 2) GFP
2-NR2E3
and RLuc, and 3) NR2E3-RLuc and GFP
2 as negative controls
(figure S3A). Additionally, we performed a BRET
2 titration curve
for each NR2E3 mutant fused with GFP
2 in presence of wild-type
NR2E3 fused to RLuc or with RLuc alone as negative control
(figure S4). The NR2E3 mutations differentially altered NR2E3
dimerization. In comparison to the NR2E3 wild-type protein, the
BRET
2 ratio was decreased by up to 70% in presence of the
p.G56R, p.R76W, p.G88V, p.R97H and p.R104Q mutant
proteins, thus indicating an impaired dimer formation. Interest-
ingly, the p.R76Q mutation increased significantly dimerization
(127.866.6%), whereas the p.R76W mutation dramatically
decreased it (30.569.0%). In contrast, the p.R104Q mutation
decreased dimerization (25.865.2%), whereas the p.R104W
mutation increased it strongly (173.564.5%). The p.R311Q
mutation located in the LBD did not alter dimerization, when
compared to the wild-type NR2E3 protein.
Next, we resorted to the same experimental approach to test
whether CRX/NR2E3 protein interactions were altered in
presence of mutations in the NR2E3 DBD. We expressed Crx-
RLuc in presence of an equal amount of each NR2E3 mutant
fused to GFP
2 (NR2E3MUT-GFP
2) (figure 4B). For negative
controls, cells were transfected with: 1) RLuc alone to measure
background fluorescence levels, 2) GFP
2-NR2E3 and RLuc, and
3) CRX-RLuc and GFP
2 (figure S3B). Additionally, we performed
a BRET
2 titration curve for each NR2E3 mutant fused to GFP
2 in
presence of wild-type CRX fused to RLuc or with RLuc alone as
negative control (figure S5). All ESCS-linked mutants, except
p.R311Q, showed a significant decrease of interaction with CRX
(50% or more). Remarkably, the CRX interaction of the adRP-
linked p.G56R mutant was comparable to that of the NR2E3
wild-type protein.
Mutations in the NR2E3 DBD abolish DNA binding
We examined whether NR2E3 mutations affected DNA-
binding. The pcDNA3.1/HisC-hNR2E3 wildtype and mutant
plasmids were in vitro transcribed/translated in reticulocyte lysates
and tested for DNA-binding by electrophoretic mobility-shift assay
(EMSA) on the reported synthetic DR1 containing two AAGTCA
half-sites [1]. No DNA-binding was observed for all seven DBD-
mutants, whereas the p.R311Q LBD-mutant was able to bind the
DNA response element (figure S6).
Impaired transcriptional activity of NR2E3 DBD mutant
proteins
We then tested the effect of the NR2E3 mutant proteins on
CRX/NRL-mediated transactivation by transient transfection
assays in HEK293T cells. CRX and NRL synergistically activate
rhodopsin, S- and M-opsin gene expression, and NR2E3 further
potentiates CRX/NRL-mediated transactivation of rhodopsin
expression by about 3-fold, but represses CRX/NRL-mediated
transactivation of S- and M-opsin expression [4,7,21].
NR2E3-dependent potentiation of CRX/NRL-mediated trans-
activation of a bovine rhodopsin promoter fragment (BR225-Luc) was
set to 100% for each experiment, and, by transfecting increasing
amounts of NR2E3 mutant proteins, we tested their effect on
rhodopsin transactivation (figure 5A). The ratios of NR2E3WT:N-
R2E3MUT were 2:1, 2:2 and 2:3. NR2E3 mutant activity could be
separated in three different groups, depending on the transactiva-
tion effect. First, the adRP-linked p.G56R mutant showed a highly
significant decrease in NR2E3WT-mediated rhodopsin transactivation
by 50% already at a NR2E3WT/NR2E3G56R ratio of 2:1 (p,0.01
by ANOVA test for p.G56R vs all other mutants). Higher
NR2E3WT/NR2E3G56R ratios (2:2 and 2:3) did not further
decrease rhodopsin promoter activity. Second, all six ESCS-linked
DBD-mutants significantly repressed NR2E3WT-mediated rhodopsin
transactivation, but to a lesser extent. Except for p.R104Q, this
repression was significant at a NR2E3WT/NR2E3MUT ratio of 2:1
(p,0.05 by ANOVA of all ESCS-linked DBD mutants vs
p.R311Q). At a NR2E3WT/NR2E3MUT ratio of 2:3, repression
Figure 2. NR2E3 homodimerization is orientation-indepen-
dent. A) HEK293T cells were transiently transfected with 3 mgo f
NR2E3-GFP
2, GFP
2-NR2E3, NR2E3-RLuc and RLuc-NR2E3 vectors, as
indicated. Control transfections were performed with renilla alone
(RLuc) and NR2E3 fused to GFP
2 (NR2E3-GFP
2 and GFP
2-NR2E3). BRET
2
ratio (grey column) and GFP
2 fluorescence (black column) were
measured and sesults were expressed as mean6SEM of 3 experiments,
p,0.003 vs. controls. B) HEK293T cells were transiently transfected with
3 mg of RLuc or NR2E3-RLuc vectors, to keep the expression level of
both proteins stable in each condition. At the same time, cells were
transfected with increasing concentrations (0.5 mgt o3mg) of GFP
2-
NR2E3 vector. BRET
2 ratio was measured and sesults were expressed as
mean6SEM of 4 experiments. (see also supplemental figure 1A). C)
Protein expression of various GFP
2-NR2E3 concentrations was assessed
by Western blot analysis using an anti-GFP antibody.
doi:10.1371/journal.pone.0007379.g002
NR2E3 In Vivo Interactions
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7379was significant for all DBD mutants (p,0.01 by ANOVA of all
ESCS-linked DBD mutants vs p.R311Q,). Third, the LBD-
mutation p.R311Q did not alter wild-type NR2E3 transactivation
at any NR2E3WT/NR2E3R311Q ratio.
With respect to repression of CRX/NRL-mediated transactiva-
tion of S- and M-opsin gene expression, the different NR2E3
mutations segregated into three different groups (figure 5B). First,
the adRP-linked p.G56R mutant repressed both promoter
fragment more efficiently than the NR2E3 wild-type protein, the
resulting S- and M-opsin promoter activity being only about 50% of
the wild-type one (p,0.0001 by ANOVA vs other mutants) [21].
Second, the ESCS-linked DBD-mutants did not significantly
repress S- and M-opsin promoter transactivation, when compared
to NR2E3 wild-type (p,0.01 by ANOVA). Third, the LBD-
mutant p.R311Q repressed S- and M-opsin promoter activity
similarly to wild-type NR2E3.
Homology modeling of the NR2E3 homodimer DNA-
binding complex
To integrate the obtained functional data into related structural
information, we performed homology modeling of the NR2E3
homodimer bound to a DR1 DNA sequence (figure 6). According
to crystallographic data obtained for RXR/RXR and RXR/RAR
dimers [28,29], the NR2E3 homodimer bound to a DR1 is
thought to interact through the a-helix of the T/A box of the 59-
monomer and the second Cys4-Zinc finger of the 39-monomer.
Figure 3. NR2E3 interacts with CRX. A) HEK293T cells were transiently transfected with 3 mg of RLuc, RLuc/GFP
2-NR2E3, GFP
2-NR2E3/Crx-RLuc
and Crx-RLuc/GFP
2 vectors. BRET
2 analysis was performed 48 h after transfection. First we quantified the GFP
2 fluorescence (at 515 nm) after an
excitation at 485 nm (upper graph in black). Then, we added the renilla luciferase substrate, Coelanterazine h, to the cell and measured the luciferase
luminescence (middle graph in white). Finally, BRET
2 ratio was measured in the four different conditions (lower graph in grey). B) HEK293T cells were
transiently transfected with 3 mg of NR2E3-GFP
2, GFP
2-NR2E3, Crx-RLuc and RLuc-Crx vectors, as indicated. Control transfections were performed with
renilla alone (RLuc) and NR2E3 fused to GFP
2 (NR2E3-GFP
2 and GFP
2-NR2E3). BRET
2 results (grey column) and GFP
2 fluorescence (black column) were
expressed as mean6SEM of 2 experiments. *p,0.0001 vs. Ctrl. C) We transfected HEK293T cells with 3 mg of RLuc or Crx-RLuc vectors to keep the
expression level of both proteins stable in each condition. At the same time, we transfected cells with increasing concentrations (0.5 mgt o2mg) of
NR2E3-GFP
2 vector. BRET
2 ratio was measured and sesults were expressed as mean6SEM of 3 experiments, *p,0.0001 vs. Ctrl (see also supplemental
figure 1B).
doi:10.1371/journal.pone.0007379.g003
NR2E3 In Vivo Interactions
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residues that are mutated in patients. Residues R76, R97 and
R104 are predicted to directly interact with DNA (figure 6A, S7
and S8). Residues R97 is, in addition, located in the second Cys4-
Zinc finger forming the dimerization interface, whereas residue
G88 is located in a loop close by (figure 6C). Notably, residue G56
is located in the b-sheets of the first Cys4-Zinc finger and spatially
segregated from the other analyzed mutations (figure 6A).
Discussion
In the present work, we analyzed by BRET
2 the effect of
disease-causing mutations located in the DBD of NR2E3. For all
NR2E3 mutants we performed a BRET
2 titration curve with a
constant concentration of donor fluorochrome and an increased
concentration of acceptor fluorochrome. This approach used in
previous BRET studies [26,30,31] provides strong support to our
proposed mechanism leading to ESCS or adRP syndromes.
Like for all NRs, mutations in the DBD of NR2E3 abolished
DNA-binding, as assessed by in vitro binding assays (figure S6).
Absence of DNA-binding is therefore insufficient to explain the
variety of clinical phenotypes observed in patients carrying
mutations in this domain (reviewed in [19]). For instance, the
adRP phenotype present in patients carrying the p.G56R
Figure 4. Role of NR2E3 DBD mutations in the dimerization
process and in the interaction with CRX. A) HEK293T cells were
transiently transfected with 2 mg of vectors expressing the wild-type
(WT) NR2E3 fused to renilla luciferase (NR2E3WT-RLuc) and with 4 mg
vector expressing mutants of NR2E3 fused to the GFP
2 (GFP
2-
NR2E3MUT). Control condition with RLuc alone and GFP
2-NR2E3WT
served to calculated the background BRET
2 ratio. Luminescence ratio
was measured as described in material and methods, and sesults were
expressed as % of GFP
2-NR2E3WT/NR2E3WT-RLuc and as mean6SEM of 3
experiments, * p,0.0001 and # p,0.01. (see supplemental figure 4 for
BRET
2 titration curve). B) HEK293T cells were transiently transfected
with 2 mg of vectors expressing the CRX fused to renilla luciferase (Crx-
RLuc) and with 4 mg of vector expressing mutants of NR2E3 fused to the
GFP
2 (NR2E3MUT-GFP
2). Control condition with RLuc alone and GFP
2-
NR2E3WT served to calculated the background BRET
2 ratio. Lumines-
cence ratio was measured as described in material and methods, and
sesults were expressed as % of NR2E3WT-GFP
2/Crx-RLuc and as
mean6SEM of 2 experiments, *p,0.003. (see supplemental figure 5
for BRET
2 titration curve).
doi:10.1371/journal.pone.0007379.g004
Figure 5. Differential transcriptional activity of NR2E3 DBD
mutants. HEK293T cells were transiently transfected with rhodopsin
(A) or S- and M-opsin (B) luciferase reporter constructs. A) NR2E3 wild-
type (NR2E3WT), CRX and NRL expression vectors (30 ng each) were
present in all wells. Transcriptional activity was tested in presence of
increasing amounts (+:15 ng; ++:30 ng; +++:45 ng) of NR2E3-DBD
mutants proteins (NR2E3m: p.G56R, p.R76Q, p.R76W, p.G88W, p.R97H,
p.R104Q, p.R104W and p.R311Q). Four to six independent experiments
were performed in duplicate in 12-well plates using the luciferase assay
system (Promega). Luciferase activity was normalized to b-galactosidase
activity. Normalized luciferase activities of cells transfected with
NR2E3WT, CRX and NRL were set to 100%. Error bars represent S.E.M.
Regression curves were performed for each NR2E3-DBD mutant and
ANOVA tests were performed (see Results section). B) NR2E3 wild-type
(WT) or above-mentioned mutants, CRX and NRL expression vectors
(30 ng each) were present in all wells except the negative control (2)
representing the background luciferase activity. Normalized luciferase
activities of cells transfected with NR2E3WT, CRX and NRL were set to
100% and sesults were expressed as means6SEM of 4–6 experiments,
*p,0.0001 and #p,0.03 for p.G56R vs. WT.
doi:10.1371/journal.pone.0007379.g005
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[20–22]. Because NR2E3 had been shown to interact with CRX
[4], we hypothesized that the transcriptional activity of CRX could
be affected by structural changes present in NR2E3 mutant
proteins. We therefore evaluated by BRET
2 analysis whether
NR2E3 DBD mutations affected the interaction with CRX
causing phenotypic variations among patients. Remarkably, the
adRP-linked p.G56R mutant protein interacted with CRX as did
the wild-type protein (figure 4B and S5). This was in sharp contrast
to all other ESCS-linked NR2E3 DBD mutant proteins, i.e.
p.R76Q, p.R76W, p.G88V, p.R97H, p.R104Q and p.R104W.
Consistent with this unique CRX interaction, the p.G56R mutant
protein repressed in HEK293T-based transient transactivation
assays the cone-specific S-opsin and M-opsin promoters, down to
levels where CRX/NRL-mediated transactivation was affected
[21]. All ESCS-linked NR2E3 DBD mutants not interacting with
CRX, i.e. p.R76Q, p.R76W, p.G88V, p.R97H, p.104Q and
p.104W, had similar transcriptional activities on rhodopsin, S- and
M-opsin promoters (figures 4 and 5). This was somewhat different
from a previous report where p.R76W and p.R97H mutant
proteins differentially interacted in vitro with CRX as assessed by
co-immunoprecipitation, but exerted the same effects on M-opsin
and rhodopsin transactivation [4].
The data presented here provide a novel molecular basis
underlying adRP caused by the p.G56R mutant protein (figure 7).
In this model the p.G56R mutant protein binds to CRX, hinders
DNA-binding of the CRX/NR2E3-p.G56R heterodimer and acts
as a repressor in trans. Because CRX is a master regulator of
photoreceptor development, titrating active CRX protein levels is
expected to have more profound effects than would the dominant
negative activity towards NR2E3 wild type protein. In support of
impaired CRX activity is not only the severe clinical phenotype of
adRP, but also the mode of inheritance, i.e. one copy of the disease
allele is sufficient to cause p.G56R-linked adRP, whereas the
recessively inherited ESCS patients are either homozygous or
compound heterozygous carriers of NR2E3 mutations.
NR2E3/CRX interactions analyzed by BRET
2 also showed the
importance of a freely accessible N-terminal DBD of CRX to
interact with NR2E3. Indeed, we observed a low energy transfer
when the Renilla luciferase was fused to the N-terminal part of
CRX (RLuc-Crx), in contrast to the Crx-RLuc fusion protein,
where high energy transfer was observed (figure 3B). We cannot
exclude that low BRET
2 signals were due to conformational
changes that affect the distance between the donor and the
acceptor, but our results are consistent with previous co-
immunoprecipitation and yeast two-hybrid assays, showing that
CRX interacts with NR2E3 through its N-terminal DBD region
[4].
In addition to abolishing DNA-binding and modulating
interaction with CRX (see above), modulation of NR2E3
homodimerization by mutations in the DBD could be an
additional factor affecting in vivo NR2E3 activity. We therefore
used BRET
2 to investigate the dimerization potential of NR2E3
wild-type and mutant proteins. BRET
2 provided the first in vivo
evidence of NR2E3 homodimerization in transiently transfected
HEK293T cells (figures 1 and 2). We did observe NR2E3 dimer
formation in non-denaturing gel electrophoresis (figure 1A), but
Figure 6. Homology modeling of the NR2E3 homodimer DNA-
binding complex. A) Ribbon view of the NR2E3 DBD homodimer
bound to a DR1. Secondary structures of the NR2E3 DBD are shown as
ribbons, i.e. starting from the N-terminus, 2 b-sheets of the first Cys4
Zinc finger, and then the 3 a-helixes extending to the C-terminus (see
supplemental Figure 4). The left NR2E3 DBD monomer is shown in
yellow-orange, and the right one in blue-green colours. Residues
mutated in patients are indicated and shown with sidechains. For the
DNA double helix all side chains are shown. Zinc ions are shown as grey
spheres. Residue G56 is located in the b-sheets of the first Cys4 Zinc
finger and spatially segregated from the other analyzed mutations. B)
Molecular surface view of the NR2E3 homodimer DNA-binding
complex. Molecular surface were represented in light-green for the
left monomer and in light-blue for the right monomer. The a-helix of
the T/A box of the left NR2E3 monomer (light green) interacts with the
second Cys4 Zinc finger of the right NR2E3 monomer (light-blue). The
DNA double helix is shown only as ribbon and colored in magenta. C)
Close-up view of the dimerization interface. Residues involved in
protein interactions are indicated and shown with sidechains. Figures
were made with DeepView 4.0 program.
doi:10.1371/journal.pone.0007379.g006
NR2E3 In Vivo Interactions
PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7379the signal corresponding to a NR2E3 dimer was weak with respect
to the signal of the monomer. The influence of gel electrophoresis
conditions on the oligomerization potential of another NR2 family
member, the retinoid X receptor, had been studied previously in
detail [32] and might underlie our observations.
The p.G56R mutant protein showed impaired dimerization
with NR2E3 wild type protein as analyzed by BRET
2 (figure 4A
and S4). This result was in contradiction with our previous in vitro
data where the p.G56R mutant protein dimerized with NR2E3
wild-type protein in EMSA analysis [21]. The new BRET
2 data
obtained in living cells is not in support of the previously suggested
dominant negative activity of the p.G56R mutant protein, but the
distinct interaction with CRX is consistent with the sesults
previously obtained in transactivation assays on rhodopsin, M- and
S-opsin promoter constructs. BRET
2 analysis performed in living
cells made it therefore possible to clarify our previous in vitro data
and to propose this new disease mechanism [21].
Consistent with the observed impaired dimerization, R97 is
located in the dimerization interface (figures 4A and 6C).
Interestingly, when DNA-interacting residues R76 and R104 are
mutated into Q or W, opposing effects on dimerization were
observed by BRET
2. Mutant proteins p.R76W and p.R104Q
showed impaired homodimerization, but not p.R76Q and
p.R104W mutant proteins. Mutating R76 abolishes two hydrogen
bonds with DNA and the presence of a bulky hydrophobic side
chain in the p.R76W mutant protein might displace the C-
terminal a ˜helix of the T/A box that forms the DBD dimerization
interface (figure S8). In contrast, the side chain of residue 104 is
directed towards the inside of the DBD, leaving intact the
dimerization interfaces. The dramatic effect of the p.G88V
mutation on NR2E3-dimerization could be due to a displacement
of the second Cys4-Zinc finger (figure 6C). However, in the
absence of crystallographic data, these interpretations remain
speculative.
In conclusion, BRET
2 has proven to be a valuable and reliable
method to analyze NR2E3 and CRX protein-protein interactions.
This functional analysis in living cells lead to further understand-
ing of potential disease mechanisms in NR2E3-linked retinal
degenerations. Figure 7 summarized hypothetic mechanisms
supported by our results (this study and [21]) and others studies
([4,7]). All analyzed mutations in the DBD disrupt DNA binding,
but the persistent association with CRX causes the adRP-linked
p.G56R mutant protein to act as a repressor of CRX in trans. The
clinical phenotype resulting from the other NR2E3 mutations in
the DBD are similar to those observed in presence of mutations in
the LBD, i.e. ESCS. We have previously shown in heterologous
Figure 7. Hypotheses about transcriptional activities of NR2E3. A) In the ‘‘normal’’ situation, wild-type NR2E3 activates rod-specific genes
(rhodopsin promoter) and represses cone-specific genes (M-opsin and S-opsin promoter) in concert with CRX and NRL. B’) In ESCS patients, rhodopsin
expression appears not to be affected in the presence of the p.R311Q LBD mutant protein. The molecular mechanism is unknown, but may involve
posttranslational modifications or differential binding to cofactors. However, repression of cone genes is released, because interaction of the p.R311Q
mutant protein with its co-repressor is impaired [4]. B0) In ESCS patients carrying mutations in the DBD, in the absence of DNA binding, NR2E3 does
not potentiate CRX/NRL-mediated rhodopsin transactivation and does not repress cone-specific gene expression. C) In adRP patients, the p.G56R
mutant protein acts as a repressor in trans of CRX-mediated photoreceptor-specfic gene expression. WT: wild type; 311Q: p.R311Q; mut*: p.R76Q,
p.R104W; mutu: p.R76W, p.G88V, p.R97H, p.R104Q; 56R: p.G56R.
doi:10.1371/journal.pone.0007379.g007
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the LBD mutant protein p.R311Q was impaired in presence of the
co-repressor atrophin [33]. The absence of NR2E3 repressor
function on cone-specific promoters very likely causes ESCS, and
at least three different molecular mechanisms may be involved: 1)
absence of NR2E3 protein because of nonsense mutations and
aberrant splicing; 2) absence of DNA binding because of mutations
in the DBD; 3) impaired corepressor binding because of mutations
in the LBD.
Recently, the dual function of NR2E3 in mature rods, i.e.
repression of cone-specific genes and activation of several rod-
specific genes, has been shown to be regulated by the E3 small
ubiquitin-related modifier (SUMO) ligase PIAS3 (protein inhibitor
of activated Stat3) [33]. PIAS3-dependent SUMOylation converts
NR2E3 into a potent repressor of cone-specific genes. Whether
NR2E3 mutations occurring in patients affect SUMOylation or
other posttranslational modifications and this, in turn, affects DNA
binding or protein-protein interactions, remains elusive and will
require further studies.
Materials and Methods
Expression vectors
Bioluminescence Resonance Energy Transfer (BRET
2) vectors,
encoding the humanized Renilla luciferase (hRluc) and the
humanized green fluorescent protein 2 (hGFP
2) were purchased
from PerkinElmer-BioSignal (Montreal, QC, Canada). The
plasmids pcDNA3.1/HisC-hNR2E3 and pcDNA3.1/HisC-
hCRX expressing the human NR2E3 and CRX, respectively,
were kindly provided by Shiming Chen [4]. To obtain all NR2E3
mutants we performed mutagenesis according to the QuikChange-
HII Site-Directed Mutagenesis Kit. Briefly, pcDNA3.1/HisC-
hNR2E3 was amplified with oligos described in Table S1 using
PfuUltra polymerase (Stratagene; Cedar Creek, TX). For RLuc-
fusion proteins, PCR amplification (oligonucleotides available on
request) of wild-type and mutants NR2E3, and CRX were
subcloned, in the hRluc-C1 or -N3 vectors, respectively. We
obtained the Rluc-NR2E3, NR2E3-Rluc, Rluc-Crx and Crx-Rluc
vectors, which express chimeric proteins. For GFP
2-fusion
proteins, PCR amplification (oligonucleotides available on request)
of wild-type and mutants NR2E3 were subcloned, in the hGFP
2-
C3 or -N3 vectors, respectively. We obtained the GFP-NR2E3
and NR2E3-GFP vectors, which express chimeric proteins. All
constructs were verified by nucleotide sequencing.
Cell Culture Condition and Transfection
Human embryonic kidney (HEK) 293T cells were cultured at
37uC in an atmosphere of 5% CO2, in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FCS, 100 U/
ml penicillin and 100 mg/ml streptomycin (#31330, Invitrogen
AG, Basel, Switzerland). For BRET
2 analyses, one day prior to the
experiment, cells were seeded in 60-mm cell culture plates at
0.8610
6 cells. One day after plating, each 60-mm plate was
transfected with the Calcium Phosphate method (ProFectionH,
Promega, Madison, WI) with 0.5 mgt o3mg of plasmid depending
of the experiment. The cells were harvested 48 h after transfection
prior to Western blot and BRET
2 analysis.
BRET
2 Assays and Fluorescence Imaging
Transfected HEK293T cells were washed with phosphate-
buffered saline (PBS), detached with trypsin/EDTA, and then
washed twice with Dulbecco’s Phosphate-Buffered Saline (D-PBS,
GIBCO, Invitrogen AG, Basel, Switzerland). Aliquots of 10
5 cells
were distributed in black 96-well microplates (Optiplate, Perki-
nElmer Life Sciences/Packard Biosciences) for fluorescence
quantification. Filter sets were 485 nm for GFP
2 excitation and
515 nm for emission. Cells expressing BRET
2 donor alone (RLuc)
were used to determine fluorescence background. Aliquots of cells
expressing same levels of fluorescence were distributed in white 96-
well microplates (Optiplate, PerkinElmer Life Sciences/Packard
Biosciences) for luminescence assay. The luciferase substrate
Coelenterazine h, DeepBlueC, (PerkinElmer/Biosignal; Montreal,
QC) was added at a final concentration of 5 mM. Filter sets were
410 nm for luciferase emission and 515 nm for GFP
2 emission.
BRET
2 ratio is defined as: [emission at 515 nm)/(emission
410 nm)] – Cf, where Cf corresponds to (emission at 515 nm)/
(emission 410 nm) for the control experiment with Rluc construct
expressed with the concerned protein fused to the GFP
2. BRET
2
ratio is expressed as raw data in experiments showing all negative
controls. Emitted fluorescence and luminescence were measured
using the Envision
H microplates reader (PerkinElmer/Biosignal,
QC, Montreal). For the GFP
2 fluorescence imaging, HEK293T
cells were analyzed under microscope with excitation
(lex=485 nm) and emission (lem=515 nm) filters.
Western Blot Analysis
HEK293T cells were cultured as described above. Then, they
were washed in PBS, suspended in 100 ml sample buffer
containing 20 mM Hepes, 0.5% Tween, phosphatase inhibitors
cocktail 1 and 2 (Sigma #p2850, #p5726; St-Louis, MO) and
CompleteH protease inhibitors (Roche Applied Science, Rotkreuz,
Switzerland). Cells were lysed with 3 successive freezing-thawing
cycles. The detergent-insoluble material was pelleted by centrifu-
gation at 15,000 rpm for 5 min at 4uC. The supernatant
containing protein cell lysates (30 mg) were used for western
blotting. For Western blot analysis, proteins were electrically
transferred to PVDF filters and incubated with anti–NR2E3
(Chemicon; Millipore AG, Switzerland) or anti–GFP (Sigma-
Aldrich; St.Louis, MO, USA). Secondary antibody, anti-rabbit-
HRP (Amersham Biosciences; Otelfingen, Switzerland), was used
to detect protein expression. Immune complexes were detected by
chemiluminescence using LumiGLO (Amersham Biosciences,
Otelfingen, Switzerland).
Transcriptional Activity
HEK293T cells were cultured as described above. Cells were
plated in 12-well plates and transfected at a confluence of 30%
with the Calcium Phosphate method (ProFectionH, Promega,
Madison, WI). Per well, 30 ng of each of the expression vectors
pcDNA3.1/HisC-hNR2E3 (wild-type, p.G56R, p.R76Q,
p.R76W, p.G88W, p.R97H, p.R104Q, p.R104W and
p.R311Q), pcDNA3.1/HisC-hCRX and pMT-NRL were used,
together with 500 ng of the luciferase reporter constructs for
rhodopsin promoter (BR225-Luc) [4], M-opsin promoter (Mop250-
Luc) [4] or S_opsin promoter (opn1sw) [4]. As internal standard,
50 ng of plasmid CMVb (Clontech, Moutain View, CA) encoding
b-galactosidase was used. To keep the total transfected DNA
quantity constant, appropriate quantities of pcDNA3.1/HisC
empty vector was added in all experiments. Enzymatic activities
were assessed with Luciferase Assay System (Promega, Madison,
WI) and standard b-Gal assay.
Homology modeling
Homology modeling was performed in project mode on the
SWISS-MODEL server (http://swissmodel.expasy.org) using
DeepView 4.0 program [34–36]. Amino acids 47–123 of human
NR2E3 (SwissProt Acc. No. Q9Y5X4) spanning the DBD were
modeled, using crystallographic data of COUP-TF DBD (PDB
NR2E3 In Vivo Interactions
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Acc. No. 1BY4) and RXR/RAR heterodimer on DR1 DNA
sequence (PDB Acc. No. 1DSZ) as templates.
Statistical Analysis
All results were expressed as means6SEM of the indicated
number of experiments. Statistical significance was calculated with
the Student’s t test and ANOVA, using Prism 4.0.2 (GraphPad
Software; La Jolla, CA).
Supporting Information
Figure S1 BRET
2 analysis of NR2E3 homodimerization and
interaction with CRX. Donor saturation curves were obtained by
measuring BRET
2 ratio in the presence of fixed quantities of
donor and increasing amounts of acceptor. In panel A, HEK293T
cells were transiently transfected with 3 mg of RLuc or NR2E3-
RLuc vectors, and an increased concentration (0.5 mgt o3mg) of
GFP
2-NR2E3 vector. While in panel B, HEK293T cells were
transiently transfected with 3 mg of RLuc or Crx-RLuc vectors and
with an increased concentration (0.5 mgt o2mg) of NR2E3-GFP
2
vector. We pooled 5 to 6 different experiments and expressed the
BRET
2 ratio ([emission at 515 nm)/(emission 410 nm)] - Cf,
where Cf corresponds to (emission at 515 nm)/(emission 410 nm)
for the control experiment with Rluc construct expressed with the
concerned protein fused to the GFP
2) in function of (GFP/GFPu)/
RLuc where GFPu correspond to the luminescence of the acceptor
in cells expressing the BRET donr alone (RLuc). In both BRET
2
experiments we reach a plateau with high acceptor concentration.
Found at: doi:10.1371/journal.pone.0007379.s001 (1.03 MB EPS)
Figure S2 Nuclear localization of NR2E3 wild-type and mutant
proteins. HEK293T cells were transiently transfected with GFP
2-
NR2E3 expression vectors. Fluorescence imaging under a Zeiss
(Axiovert 200) inverted microscope was used to detect GFP
2
fluorescence. Wild-type and mutant NR2E3 proteins were
correctly localized to the nucleus.
Found at: doi:10.1371/journal.pone.0007379.s002 (3.73 MB EPS)
Figure S3 Comparable expression levels of NR2E3 wild-type
and mutant proteins in transiently transfected HEK293 cells. (A)
HEK293T cells were transiently transfected with vectors express-
ing the wild-type NR2E3 (WT) fused to renilla luciferase
(NR2E3WT-RLuc) and with mutants of NR2E3 fused to the
GFP
2 (GFP
2-NR2E3MUT). Fluorescence of the GFP
2 was
measured to ensure an equal expression of GFP
2 alone and
GFP
2-NR2E3x chimera proteins in each condition. Results were
expressed as % of GFP
2-NR2E3WT/NR2E3WT-RLuc and as a
mean6SEM of 3 experiments. (B) HEK293T cells were
transiently transfected with vectors expressing the CRX fused to
renilla luciferase (Crx-RLuc) and with mutants of NR2E3 fused to
the GFP
2 (NR2E3MUT-GFP
2). Fluorescence of the GFP
2 was
measured to ensure an equal expression of GFP
2 alone and GFP
2-
NR2E3x chimera proteins in each condition. Results were
expressed as % of GFP
2-NR2E3WT/Crx-RLuc and as a mean6
SEM of 2 experiments.
Found at: doi:10.1371/journal.pone.0007379.s003 (1.26 MB EPS)
Figure S4 BRET
2 titration curves of NR2E3 mutants in the
NR2E3 dimerization. For each NR2E3 mutant, we transfected
293T cells with 2 I ˆJg of RLuc alone (RLuc) or fused to NR2E3
(RLuc-NR2E3WT) and an increasing amount (0.5 to 4 I ˆJg) of the
NR2E3 wild-type or mutants fused to the GFP
2 (GFP
2-NR2E3WT
or GFP
2-NR2E3MUT). Sigmoidal regression curves were per-
formed for all graphs.
Found at: doi:10.1371/journal.pone.0007379.s004 (1.25 MB
DOC)
Figure S5 BRET
2 titration curve of NR2E3 mutants in
NR2E3/CRX interation. For each NR2E3 mutant we transfected
293T cells with 2 I ˆJg of RLuc alone (RLuc) or fused to CRX
(CRX-RLuc) and an increasing amount (0.5 to 4 I ˆJg) of the
NR2E3 wild-type or mutant fused to the GFP
2 (NR2E3WT-GFP
2
or NR2E3MUT-GFP
2). Sigmoidal regression curves were per-
formed for all graphs.
Found at: doi:10.1371/journal.pone.0007379.s005 (2.03 MB EPS)
Figure S6 Mutations in the DBD impair DNA binding. NR2E3
wild-type and mutants proteins were in vitro transcribed/translated
in reticulocyte lysates (TNT; Promega).; In vitro DNA-binding of
NR2E3 proteins was tested on a radiolabeled consensus DR1
response element [1] with a 100-fold excess of either non-specific
(2) or specific (+) competitor oligonucleotides. One I ˆJlo f
programmed reticulocyte lysate was used per binding reaction.
Transcription/translation efficiency was tested by western blot
analysis (data not shown). The migration of the complex formed
by binding of the NR2E3 dimer to the probe is indicated by a
black arrow. DNA binding is only detected in the presence of wild-
type NR2E3 and the LBD-mutant p.R311Q (low level of detection
was observed for the p.R311Q mutant in this experiment, but
higher exposition and published studies [21] showed clearly a
DNA-binding for the p.R311Q mutant). All DBD mutants, i.e.
p.G56R, p.R76Q, p.R76W, p.G88V, p.R97H, p.R104Q and
p.R104W, did not bind to DNA. The radiolabeled probe
was obtained by annealing oligonucleotides NR2E3REfor
(59-CCTTTAAAAGTCAAAAGTCAACTTCCAA-39) and
NR2E3RErev (59-TTCCGTTGGAAGTTGACTTTTGACT-
TTT-39). Radiolabeling by Klenow fill-in with 30 I ˆJCi of
[I ˆ6-
32P]dATP (3000 Ci/mmol) (Hartmann Analytik, Braunsch-
weig) and subsequent probe purification on Sephadex G-50
columns was according to manufacturers instructions (Roche,
Basel, Switzerland). DNA-binding reactions were carried out
in 20 I ˆJl of 10 mM Tris (pH 7.5), 160 mM KCl, 1 mM
dithiothreitol (DTT), 10% glycerol, 10 I ˆJg of sonicated salmon
sperm DNA (Roche), 2 I ˆJg of poly(dI-dC) and 1 I ˆJlo f
programmed reticulocyte lysate. After a 15-min incubation on ice,
1n g o f
32P-labeled probe was added, and incubations were
continued for an additional 15 min at room temperature. DNA-
protein complexes were separated from free probe on a native 4%
polyacrylamide gel in 0.5 x Tris/borate/EDTA (TBE) buffer. Gels
were dried and revealed by phosphorimaging (GE Healthcare,
Piscataway, NJ).
Found at: doi:10.1371/journal.pone.0007379.s006 (1.73 MB EPS)
Figure S7 Amino acid sequence alignment of human NR2E3
(PNR) and NR2B1 (RXRI ˆ6) DNA-binding domains (DBDs). The
NR2E3 DBD (residues 47–123 of SwissProt Acc. No. Q9Y5X4)
exhibits a sequence identity of 57.1% (44 residues) and a sequence
similarity of 80.5% (62 residues) with the RXRI ˆ6DBD (residues
135–210 of SwissProt Acc. No. P19793). The main regions of the
DBD, i.e. the two Cys4 Zn-fingers and the so-called T/A box, are
indicated above the sequence alignment. Disease-causing muta-
tions are indicated above the NR2E3 sequence. Given the high
sequence homology, the structural data obtained for RXRI ˆ6 were
also indicated on the NR2E3 sequence [27,28]. Residues directly
interacting with DNA are highlighted in yellow. Residues directly
involved in protein-protein interactions in the RXR homodimer
are highlighted in blue. Residues involved in both DNA-binding
and RXR dimerization are highlighted in grey. The I ˆ6-helical
regions are underlined. The I ˆ6-helical region extending from the
C-terminus of the first Cys4 Zn-finger is called recognition helix
NR2E3 In Vivo Interactions
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The residues of the P-box are shown in italics. In the N-terminus
of the second Cys4 Zn-finger, the residues of the D-box involved in
dimerization are also shown in italics. A second I ˆ6-helical region
extends from the C-terminus of the second Cys4 Zn-finger. The
third I ˆ6-helix is a part of the so-called T/A box that extends
beyond the region for which crystallographic data are available.
Sequences were aligned with the CLUSTAL W 2.0 algorithm.
Polar residues are shown in green, non-polar residues in red, basic
residues in magenta, and acidic residues in blue. Below the
sequence alignment, (*) denotes sequence identity, (:) denotes
conserved substitutions, and, (.) denotes semi-conserved substitu-
tions.
Found at: doi:10.1371/journal.pone.0007379.s007 (1.00 MB EPS)
Figure S8 Mutation analysis by homology modeling of the
NR2E3 homodimer DNA-binding complex. Amino acids 47–123
of human NR2E3 (SwissProt Acc. No. Q9Y5X4) were used for
homology modelling on the SWISS-MODEL server with Deep-
View program (http://swissmodel.expasy.org) [30–32]. Crystallo-
graphic data of COUP-TF DBD (PDB Acc. No. 2EBL), RXR
homodimer on DR1 DNA sequence (PDB Acc. No. 1BY4) and
RXR/RAR heterodimer on DR1 DNA sequence (PDB Acc.
No. 1DSZ) were used as templates. Secondary structures of the
NR2E3 DBD monomer are shown as ribbons, i.e. starting from
the N-terminus, 2 b-sheets of the first Cys4 zinc finger in green-
yellow, the a-helix located in C-terminus of the first Cys4 zinc
finger in yellow, the second a-helix located in C-terminus of the
second Cys4 zinc finger in orange and the C-terminal a-helix of
the T/A box in red (see also supplemental Figure 4). Residues
p.R76 (left panels) and p.R104 (right panels) are shown with
sidechains. For the DNA double helix all side chains are shown.
Zinc ions are shown as small grey spheres. Residue p.R76 (left,
upper panel) is located at the very C-terminus of the a-helix
located in C-terminus of the first Cys4 zinc finger and directly
contacts DNA through two hydrogen bonds (green dotted line).
Both p.R76Q and p.R76W mutations disrupt hydrogen bond
formation (left, middle and lower panels). The most favoured
rotamers of the mutated residues all point towards the C-terminal
a-helix of the T/A box. The bulky hydrophobic Trp sidechain
might therefore impede dimerization. Residue p.104 (right, upper
panel) is located in the middle of the a-helix located in C-terminus
of the second Cys4 zinc finger. The sidechain points towards the
inside of the protein, also in presence of the p.R104Q and
p.R104W mutations (left, middle and lower panels).
Found at: doi:10.1371/journal.pone.0007379.s008 (5.25 MB EPS)
Table S1 PCR primers used for NR2E3 mutagenesis.
Found at: doi:10.1371/journal.pone.0007379.s009 (1.43 MB EPS)
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